David Geller, M.D.

Vice President, Pulmonary and Rare Diseases at Arcturus Therapeutics

Speaker

David Geller, MD is the lead for Pulmonary and Rare Diseases clinical development at Arcturus Therapeutics, a clinical-stage messenger RNA medicines and vaccine company focused on targeting the root cause of respiratory and rare diseases. Arcturus achieved approval for a COVID-19 vaccine last year, the first vaccine to use self-amplifying mRNA. Arcturus’ current clinical programs include an mRNA therapeutic for ornithine transcarbamylase (OTC) deficiency, a urea cycle defect, and inhaled mRNA replacement therapy for cystic fibrosis.

After training in Pediatrics at UCLA and in Pediatric Pulmonology at the University of Arizona, David spent over 25 years devoted to the care of patients with CF and complex pulmonary problems. He served as CF Center Director at Nemours Children’s Clinic in Orlando, Florida, where he founded the Aerosol Research Laboratory to investigate more efficient ways of delivering medicines to the lungs. Due to his passion to find life-changing medicines for patients with unmet needs, he spent 7 years at AbbVie leading the CF program R&D effort, and then transitioned in 2020 to his current position in Biotech at Arcturus.